Can a new drug help when standard chemo leaves cancer behind?
NCT ID NCT00877500
First seen Nov 11, 2025 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This study tests whether the drug ixabepilone can help people with HER2-negative breast cancer who still have significant cancer after standard chemotherapy. About 116 participants will either receive ixabepilone or standard care. The goal is to see if ixabepilone improves outcomes and to understand which tumors might respond best.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advocate Christ Medical Center
Oak Lawn, Illinois, 60453-2699, United States
-
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ixabepilone (a chemotherapy drug that blocks cell division)
What this could lead to
If it works, this could provide a new treatment option for breast cancer patients who still have cancer after initial chemotherapy.
What could go wrong
This is a small, early-phase trial (116 participants) and may not show a clear benefit. Ixabepilone can cause side effects like nerve damage and low blood cell counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.